GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Biologic Products Holdings Inc (NAS:CBPO) » Definitions » Owner Earnings per Share (TTM)

China Biologic Products Holdings (China Biologic Products Holdings) Owner Earnings per Share (TTM) : 4.19 (As of Sep. 2020)


View and export this data going back to 2001. Start your Free Trial

What is China Biologic Products Holdings Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

China Biologic Products Holdings's Owner Earnings per Share (TTM) ended in Sep. 2020 was $4.19. It's Price-to-Owner-Earnings ratio for today is 28.64.


The historical rank and industry rank for China Biologic Products Holdings's Owner Earnings per Share (TTM) or its related term are showing as below:

CBPO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.49   Med: 28.45   Max: 201.86
Current: 28.45


During the past 13 years, the highest Price-to-Owner-Earnings ratio of China Biologic Products Holdings was 201.86. The lowest was 21.49. And the median was 28.45.


CBPO's Price-to-Owner-Earnings is not ranked
in the Biotechnology industry.
Industry Median: 33.89 vs CBPO: 28.45

China Biologic Products Holdings's Earnings per Share (Diluted) for the three months ended in Sep. 2020 was $0.99. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $3.58. It's PE Ratio ratio for today is 33.52.

China Biologic Products Holdings's EPS without NRI for the three months ended in Sep. 2020 was $0.99. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2020 was $3.58. It's PE Ratio without NRI ratio for today is 33.52.


China Biologic Products Holdings Owner Earnings per Share (TTM) Historical Data

The historical data trend for China Biologic Products Holdings's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biologic Products Holdings Owner Earnings per Share (TTM) Chart

China Biologic Products Holdings Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.79 1.80 0.91 0.73 3.70

China Biologic Products Holdings Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.04 3.70 4.79 4.70 4.19

Competitive Comparison of China Biologic Products Holdings's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, China Biologic Products Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Biologic Products Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where China Biologic Products Holdings's Price-to-Owner-Earnings falls into.



China Biologic Products Holdings Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

China Biologic Products Holdings's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 141.1
Depreciation, Depletion and Amortization 27.3
Change In Deferred Tax -1.7
5Y Average of Maintenance Capital Expenditure 29.1
Change In Working Capital 28.0
Shares Outstanding (Diluted Average) 39.5

1. Start with "Net Income" from income statement. China Biologic Products Holdings's Net Income for the trailing twelve months (TTM) ended in Sep. 2020 was $141.1 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. China Biologic Products Holdings's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2020 was $27.3 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. China Biologic Products Holdings's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2020 was $-1.7 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $29.1 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

China Biologic Products Holdings's 5-Year Average Maintenance Capital Expenditure = $29.1 Mil

5. "Change In Working Capital" is from cashflow statement. China Biologic Products Holdings's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2020 was $28.0 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. China Biologic Products Holdings's Shares Outstanding (Diluted Average) for the months ended in Sep. 2020 was 39.536 Mil.

China Biologic Products Holdings's Onwer Earnings Per Share for Sep. 2020 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 141.063 +27.264+-1.729
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-29.095605972608+27.957)/39.536
=4.19

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=119.99/4.19
=28.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


China Biologic Products Holdings Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of China Biologic Products Holdings's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


China Biologic Products Holdings (China Biologic Products Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19 Chaoyang Park Road, 18th Floor, Jialong International Building, Chaoyang District, Beijing, CHN, 100125
China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.
Executives
Zhijing Cbpo Liu officer: Corporate Vice President 19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125
Sean Shao director 21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040
David Gao director, officer: Chief Executive Officer C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Albert Yeung director C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
David Hui Li director C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017
Min Fang director UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002
Zhijun Tong director C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Joseph Chow director 10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121
Yungang Lu director 4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086
Warburg Pincus Llc 10 percent owner 450 LEXINGTON AVENUE, NEW YORK NY 10017
Wp X Biologics Llc director, 10 percent owner C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017
Warburg Pincus X Partners, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus Private Equity X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X Gp L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017

China Biologic Products Holdings (China Biologic Products Holdings) Headlines